new blood-thinning drug prasugrel appears better for diabetes
Eli Lilly (LLY.N: Quote, Profile, Research, Stock Buzz) and Daiichi Sankyo’s (4568.T: Quote, Profile, Research, Stock Buzz) new blood-thinning drug prasugrel appears better for diabetes patients than Plavix, researchers said on Sunday.
Prasugrel — a rival to Plavix from Sanofi-Aventis (SASY.PA: Quote, Profile, Research, Stock Buzz) and Bristol-Myers Squibb (BMY.N: Quote, Profile, Research, Stock Buzz) — is a key product for Lilly and Daiichi. But its path to market has been delayed and the drug has been associated with serious bleeding.